Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The present study was conducted to find out whether the bioavailability of 0.25 mg
pramipexole tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals was
equivalent to the reference drug (Sifrol® tablet 0.25 mg, Boehringer Ingelheim Pharma GmbH &
Co. KG, Germany for Boehringer Ingelheim International GmbH, Germany).